Background: Ultrasensitive prostate-specific antigen (PSA) is a significant serum biomarker for identifying the PSA nadir and early biochemical failure after radical prostatectomy (RP). We assessed the efficiency of ultrasensitive PSA assay in the follow-up after RP. Methods: We generated longitudinal ultrasensitive PSA data using a computer program assuming that patients experienced biochemical failure after RP. The simulation experiments, based on several different scenarios, were performed to assess the sensitivity and specificity in the diagnosis of biochemical failure using ultrasensitive PSA values and to estimate the lead time, which is the time advantage of detecting positivity for biochemical failure using the ultrasensitive PSA values compared with conventional PSA assay. We validated the sensitivity, specificity and lead time using actual follow-up data of 182 patients receiving RP. Results: It was suggested that the sensitivity obtained from the actual data was more similar to that obtained using ultrasensitive PSA with an exponential increase than with a linear increase in the simulation experiments. Diagnosing biochemical failure based on two consecutive increases in the ultrasensitive PSA values was not recommended. Of nonbiochemical failure patients, 9.4% showed four consecutive increases in their ultrasensitive PSA values. Average lead time in the actual data was 11.2 months (SD: 10.1). Conclusions: For an accurate diagnosis of biochemical failure, our findings suggest the importance of a certain duration of follow-up and exclusion of false-positive results afterwards.
INTRODUCTION
Recently prostate cancer has been increasingly detected earlier, which is attributable to the widespread use of prostate-specific antigen (PSA) screening. In addition, there has been a downward stage migration in patients diagnosed with prostate cancer (1) . Previous studies reported that 15 -39% of patients experienced biochemical failure after radical prostatectomy (RP) (2, 3) . Freeland et al. reported that patients with post-operative PSA values greater than 0.2 ng/ ml are at a very high risk of developing an additional increase in PSA (4), whereas Stephenson et al. reported that biochemical failure defined as a PSA value of 0.4 ng/ml followed by another increase best predicts the development of distant metastasis (5) . Some institutions have used the newly developed ultrasensitive PSA assay after RP instead of the conventional one. The third-generation ultrasensitive PSA assay is capable of measuring PSA levels below 0.02 ng/ml (6) . The Immulite third-generation PSA assay (Diagnostic Products Corp., Los Angeles, California) is an assay with the lower limit of detection of 0.003 ng/ml (7) . Several investigators reported that the ultrasensitive PSA nadir predicted the risk of early biochemical failure (8 -10) . It is reported that time to ultrasensitive PSA nadir also predicts early biochemical failure (10) . However, the definition of biochemical failure using ultrasensitive PSA values after RP has not been standardized. Yu et al. (8) defined biochemical failure using ultrasensitive PSA values after RP as: (1) two or more consecutive increases in ultrasensitive PSA values that resulted in at least doubling of the initial ultrasensitive PSA value, (2) any increases that resulted in ultrasensitive PSA values greater than 0.1 ng/ml, or (3) a 10-fold increase in ultrasensitive PSA values between two measurements. However, this definition has not been widely accepted yet. At present, only consecutive increases in ultrasensitive PSA values are recommended to diagnose biochemical failure (11) . Recently, salvage radiotherapy has been reported to be initiated for patients with lower ultrasensitive PSA values (12) . However, it is not known whether or not these treatments have contributed to survival.
As the first step to avoid overtreatment in the postoperative follow-up, it is important to grasp the sensitivity, specificity and time advantage of ultrasensitive PSA assay in diagnosing biochemical failure. We tried to predict these outcomes by simulation experiments on computer program and validate the results using actual clinical data.
METHODS

DATA GENERATION
Using random numbers, we generated the longitudinal ultrasensitive PSA data assuming that the patients experienced biochemical failure after RP. The exponential or linear increases in ultrasensitive PSA values are assumed in the following formula (13) . An error term e in model (a) was assumed to be normally distributed with mean 0 and variance s 2 , i.e. e $ N(0, s 2 ). In order to make the variance of PSA in model (a) and that of PSA 0 in model (b) equal, an error term (e 0 ) in model (b) was defined as randomly generated PSA in model (a) minus the expected PSA in model (a). When time ¼ 0, the intercept parameter exp(b 0 ) in model (a) or b 0 0 in model (b) was set to be 0.003 ng/ml as the value of post-operative ultrasensitive PSA nadir. The value of the standard deviation (SD), s, was chosen in terms of the coefficient of variation (CV), the value of which was obtained from the reproducibility test in the brochure and previous studies (7, 14) . CV was obtained by measuring the same sample five to ten times with different kinds of ultrasensitive PSA kits. We fixed the prostatespecific antigen doubling time (PSADT) as the speed of tumor recurrence, and then the longitudinal ultrasensitive PSA data were randomly generated according to model (a) or (b). A computer program was written to generate random numbers using SAS Ver.9.1.3.
SETTINGS OF SIMULATIONS
We performed two simulation experiments to assess the sensitivity, specificity and lead time. The scenarios of each simulation experiment are shown in Tables 1 and 2 . Longitudinal ultrasensitive PSA data of 1000 patients for the combinations of each scenario were generated using random numbers. In the first simulation experiment (Simulation 1), the value of PSADT in the biochemical failure group was set at 3, 6, 9 or 12 months, while that of patients in the control group, who had no recurrence, was set at 120 months. In the exponential increase, b 1 of 3, 6, 9, 12, or 120 months of PSADT was set at 2. , or 2.5 Â 10 25 respectively. Positivity for biochemical failure was defined as two, three, or four consecutive increases in ultrasensitive PSA values. The duration of follow-up was set at 12 or 24 months, and the interval of ultrasensitive PSA measurements was set at 3 months. We chose the SD of s ¼ 0.075 (best case) or s ¼ 0.15 (worst case). The duration of follow-up in Simulation 2 was defined as the time to positivity for biochemical failure identified using an ultrasensitive PSA assay.
In the second simulation experiment (Simulation 2), all the data were generated as the biochemical failure group. Positivity for biochemical failure was defined as three consecutive increases in ultrasensitive PSA values. Biochemical failure was defined as having a PSA value greater than 0.2 ng/ml, which was the lower limit of detection of the Hybritech Tandem-R assay (s ¼ 0.075). The duration of follow-up was defined as the time to positivity identified using an ultrasensitive PSA assay. The interval of ultrasensitive PSA measurements and SD (s) were set at the same values as those of model (a) in Simulation 1.
OUTCOME MEASURE FOR SIMULATIONS
In Simulation 1, the sensitivity and specificity were assessed in each scenario. The sensitivity was defined as the probability of enabling the identification of positivity in the biochemical failure group during the duration of follow-up. The specificity was defined as the probability of negativity being identified in the control group during the duration of follow-up.
In Simulation 2, we calculated the average lead time, which is the time difference between positivity identified using the ultrasensitive PSA assay and biochemical failure identified using the conventional PSA assay. A graphical representation of lead time is shown in Figure 1 .
VALIDATION OF SIMULATION RESULTS USING ACTUAL DATA
Between January 1999 and December 2004, 302 men with a clinically localized prostate cancer underwent radical retropubic prostatectomy at two institutions. Of these patients, 120 were excluded from the validation data set owing to insufficient follow-up in 48 men, administration of adjuvant therapy in 40 men, follow-up using a conventional assay in 24 men and the ultrasensitive PSA nadir being 0.05 ng/ml or more in 8 men. The remaining 182 patients were postoperatively followed every one to three months using an ultrasensitive assay and were included in the current analysis. Of these patients, 23 (12.6%) experienced biochemical failure. Biochemical failure was defined as PSA being greater than 0.2 ng/ml. Positivity for biochemical failure was defined as two, three or four consecutive increases and we calculated the sensitivity and specificity in biochemical failure. We also calculated the time difference between the time to positivity, which was defined as three consecutive increases and the time to a value greater than 0.2 ng/ml.
RESULTS
We assessed the sensitivity, specificity, and lead time using the longitudinal ultrasensitive PSA data generated with random numbers. The results of Simulation 1 are shown in Tables 3 and 4 .
The sensitivity differed remarkably between the exponential and linear increases in ultrasensitive PSA values. In the exponential increases, as the duration of follow-up became longer, the sensitivity increased in all scenarios. However, the sensitivity decreased with the increasing number of consecutive increases. In the linear increases, when positivity for biochemical failure was defined as three or four consecutive increases, the sensitivity presented as a remarkably low value without being influenced by the duration of follow-up. In contrast to the sensitivity, the specificity did not differ remarkably between the exponential and linear increases in ultrasensitive PSA values. The results of specificity based on two consecutive increases presented low value without being influenced by the duration of follow-up. The sensitivity and specificity which were calculated using actual data are shown in Table 5 . The sensitivity obtained from the assumption that ultrasensitive PSA increased exponentially in Simulation 1 was more similar to the sensitivity obtained from the actual data than that in which the linear increases were assumed. Of the biochemical failure group, 0%, 4.3% and 13.0% did not experience two, three and four consecutive increases, respectively. However, of the no recurrence group, 42.8%, 18.9% and 9.4 % experienced two, three and four consecutive increases, respectively. In Simulation 2 and the actual data, the lead time between positivity identified using the ultrasensitive PSA assay and biochemical failure identified using the conventional PSA assay is shown in Table 6 . The average lead time was approximately 5 years when the value of PSADT was 12 months in the simulation data. The average of PSADT in patients who experienced biochemical failure in the actual data was 5.6 months. The average, minimum and maximum lead time in the actual data was 11.2, 0 and 38.0 months, respectively. 
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Efficiency of post-operative ultrasensitive PSA Range of the sensitivity and specificity were composed of the results of different standard deviation. Standard error was 1.6 (%) where the sensitivity or specificity was 50 (%) in 1000-time iterations for each scenario. Range of the sensitivity and specificity were composed of the results of different standard deviation. Standard error was 1.6 (%) where the sensitivity or specificity was 50 (%) in 1000-time iterations for each scenario.
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DISCUSSION
There has been an increase in the number of patients receiving salvage radiotherapy for biochemical failure after RP. In the past, these patients had been administered salvage radiotherapy after clinical local recurrence (15) . Recently, Cheung et al. reported that earlier initiation of salvage radiotherapy after post-operative biochemical failure led to a good outcome (16) . However, if biochemical failure is identified using low ultrasensitive PSA values, unnecessary salvage therapies may be administered to the false-positive patients.
In addition, some of the patients whose life expectancy is not long may not even require salvage therapy. We hypothetically set up the biochemical failure group and assessed the efficiency of ultrasensitive PSA assay after RP through Monte Carlo simulation experiments. Increases in conventional PSA values after RP have been reported to represent an exponential growth curve (3, 17) , whereas the significance of those in ultrasenstive PSA values has remained unproven until the present. The sensitivity of actual data more closely resembled the result from exponential increases rather than that from linear increases in biochemical failure after RP in Simulation 1. More specifically, it was suggested that PSADT assuming an exponential increase might be more suitable for predicting post-operative biochemical failure using an ultrasensitive PSA assay than PSA velocity assuming a linear increase. Next, using actual data, some patients experienced biochemical failure without identifying four consecutive increases in ultrasensitive PSA values which represented false-negative, whereas other patients were free of biochemical failure, even if four consecutive increases were confirmed, which represented false-positive. We need to reduce false-positivity in the post-operative follow-up, because the situation is different from screening. Therefore, it is required to extend the duration of follow-up and then increase the number of consecutive increase in ultrasensitive PSA values. Shinghal et al. reported a significant variation in ultrasensitive PSA values after RP without clinical progression during long-term follow-up (18). Djavan et al. reported that given the small amount of PSA produced and the lack of PSA progression, residual benign glands and periurethral glands might be the source of PSA (19) . Accordingly, salvage therapies should be adapted carefully. Although using an ultrasensitive PSA assay is helpful for grasping post-operative PSA nadir as compared with conventional PSA, it may be difficult to define biochemical failure using consecutive increases in ultrasensitive PSA values.
In our data, ultrasensitive PSA assay enabled a time advantage of 11.2 months to be gained in the diagnosis of biochemical failure. It has been reported in previous studies that the lead time of biochemical failure identified using ultrasensitive PSA and conventional PSA assays ranged from 10 to 29 months (6, 20) . However, these values were averages and differences arising from the speed of tumor recurrence were not taken into consideration. Several investigators reported that the value of PSADT at biochemical failure after RP might be the surrogate endpoints for a prostate cancer-specific mortality or a predictor of biochemical outcome for salvage radiotherapy (21 -24) . We estimated the lead time by PSADT in Simulation 2. Pound et al. (3) reported that the median actuarial time to clinical metastasis 
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Efficiency of post-operative ultrasensitive PSA was 8 years from the time of elevation of the PSA level after RP and that once men developed metastatic disease, the median actuarial time to death was 5 years. Using the ultrasensitive PSA assay, the time from positivity for biochemical failure after RP to death will be much longer. D'Amico et al. reported that patients with a post-operative PSADT of more than 12 months might not require salvage radiotherapy (25) . The estimated lead time in Simulation 2 may help in making decisions on salvage therapies that appropriately correspond to life expectancy. However, we need to recognize the instability of the calculated PSADT arising from the imprecision of the ultrasensitive PSA assay compared with the conventional assay.
We admit a limitation of our study that we could not estimate the sensitivity and lead time using actual data stratified by PSADT, because there were few patients with biochemical failure who did not receive adjuvant therapy after RP.
In conclusion, although using an ultrasensitive PSA assay in post-operative monitoring may make early detection of a biochemical failure possible, the risk associated with the administration of unnecessary therapy will also increase. In order to diagnose the biochemical failure correctly, our findings suggest it is important to resort to a certain duration follow-up, and then introduce salvage therapies carefully.
